NCT00003568View on ClinicalTrials.gov

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 1998

Study Completion Date

December 31, 2005

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

Trial Locations (9)

10466

Comprehensive Cancer Center at Our Lady of Mercy Medical CenterOur, The Bronx

15236

University of Pittsburgh Cancer Institute, Pittsburgh

60153

Loyola University Medical Center, Maywood

60612

University of Illinois at Chicago Health Sciences Center, Chicago

91010-0269

City of Hope Comprehensive Cancer Center, Duarte

02215

Beth Israel Deaconess Medical Center, Boston

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

37232-2516

Vanderbilt University Medical Center, Nashville

78229-3900

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Illinois at Chicago

OTHER

NCT00003568 - Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter